Aspire Biopharma Holdings Inc (ASBP)

$1.63 -0.07 (-4.12%)
Market Cap 5.72M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.54
Volume 405,100
Avg Vol 1,058,077
Day's Range N/A - N/A
Shares Out 2.69M
Stochastic %K 21%
Beta 0.81
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
METS1
METS1 Feb. 4 at 5:06 AM
$ASBP I personally would not do any business in California , because if they Gov't, I will go to Texas or Florida
0 · Reply
todayatatime
todayatatime Feb. 4 at 2:23 AM
$ASBP if not tomorrow we ride friday...!. if we can get 10+ we may be able hold over 10!!!! Keep some powder ready as they say
1 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 11:07 PM
$ASBP who ever is at $1.65 is going to loose thiere shares
1 · Reply
todayatatime
todayatatime Feb. 3 at 10:13 PM
$ASBP tomorrow technically �or �friday or :)
0 · Reply
Ricx88
Ricx88 Feb. 3 at 9:44 PM
$ASBP here's the play. Volume dries up shorts get trapped, notable news drops forcing the squeeze. Hold on your your hats folks it's gonna be a slow few days but it'll be worth it $6+ im
0 · Reply
lecorb
lecorb Feb. 3 at 9:28 PM
$ASBP Last update : 9 minutes ago Time Since Last Change Timestamp (UTC) US:ASBP Short Shares Availability 10 minutes ago 2026-02-03 21:16:34.7 7,000 2 hours ago 2026-02-03 18:36:00.422 6,000 3 hours ago 2026-02-03 18:04:08.61 15,000 1 day ago 2026-02-02 13:02:57.123 0 1 day ago 2026-02-02 12:32:57.123 2,000 1 day ago 2026-02-02 06:18:22.529 3,000 7 days ago 2026-01-27 13:05:10.037 0 7 days ago 2026-01-27 07:47:19.914 10,000 7 days ago 2026-01-27 02:10:16.235 4,000 8 days ago 2026-01-26 15:12:06.829 6,000
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 9:14 PM
$ASBP Yeah the short on this stock is huge, but look this morning we where $2.01 premarket, this must short we get squeezed by a capital group for a major run!!!
0 · Reply
METS1
METS1 Feb. 3 at 9:09 PM
$ASBP You can see all the lies the short sellers that ASBP is garbage. Just look at all patient that's in the pipe line. They would already approved by the FDA a few weeks ago and I believe they will get more approval for more patients. The short sellers keep saying sh** so you will sell you shares to bring they stock price down so that they make more money then you, do your homework.
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 9:08 PM
$ASBP may be an after hours move here
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 8:36 PM
$ASBP https://www.nasdaq.com/market-activity/stocks/asbp/sec-filings
0 · Reply
Latest News on ASBP
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 17 hours ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 5 days ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 7 days ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 12 days ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 13 days ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 14 days ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 20 days ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 27 days ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 7 weeks ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 2 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 2 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 2 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 3 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 4 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 2, 2025, 2:44 PM EDT - 4 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 4 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 6 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 6 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025, 8:00 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Apr 14, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Apr 11, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 9, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Mar 20, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Mar 13, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Mar 11, 2025, 8:00 AM EDT - 11 months ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Mar 3, 2025, 7:30 AM EST - 1 year ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Feb 25, 2025, 7:30 AM EST - 1 year ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Feb 20, 2025, 6:15 PM EST - 1 year ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

METS1
METS1 Feb. 4 at 5:06 AM
$ASBP I personally would not do any business in California , because if they Gov't, I will go to Texas or Florida
0 · Reply
todayatatime
todayatatime Feb. 4 at 2:23 AM
$ASBP if not tomorrow we ride friday...!. if we can get 10+ we may be able hold over 10!!!! Keep some powder ready as they say
1 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 11:07 PM
$ASBP who ever is at $1.65 is going to loose thiere shares
1 · Reply
todayatatime
todayatatime Feb. 3 at 10:13 PM
$ASBP tomorrow technically �or �friday or :)
0 · Reply
Ricx88
Ricx88 Feb. 3 at 9:44 PM
$ASBP here's the play. Volume dries up shorts get trapped, notable news drops forcing the squeeze. Hold on your your hats folks it's gonna be a slow few days but it'll be worth it $6+ im
0 · Reply
lecorb
lecorb Feb. 3 at 9:28 PM
$ASBP Last update : 9 minutes ago Time Since Last Change Timestamp (UTC) US:ASBP Short Shares Availability 10 minutes ago 2026-02-03 21:16:34.7 7,000 2 hours ago 2026-02-03 18:36:00.422 6,000 3 hours ago 2026-02-03 18:04:08.61 15,000 1 day ago 2026-02-02 13:02:57.123 0 1 day ago 2026-02-02 12:32:57.123 2,000 1 day ago 2026-02-02 06:18:22.529 3,000 7 days ago 2026-01-27 13:05:10.037 0 7 days ago 2026-01-27 07:47:19.914 10,000 7 days ago 2026-01-27 02:10:16.235 4,000 8 days ago 2026-01-26 15:12:06.829 6,000
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 9:14 PM
$ASBP Yeah the short on this stock is huge, but look this morning we where $2.01 premarket, this must short we get squeezed by a capital group for a major run!!!
0 · Reply
METS1
METS1 Feb. 3 at 9:09 PM
$ASBP You can see all the lies the short sellers that ASBP is garbage. Just look at all patient that's in the pipe line. They would already approved by the FDA a few weeks ago and I believe they will get more approval for more patients. The short sellers keep saying sh** so you will sell you shares to bring they stock price down so that they make more money then you, do your homework.
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 9:08 PM
$ASBP may be an after hours move here
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 8:36 PM
$ASBP https://www.nasdaq.com/market-activity/stocks/asbp/sec-filings
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 8:28 PM
$ASBP This definitely the price to load up at, not sell
0 · Reply
Leo70o
Leo70o Feb. 3 at 8:23 PM
$ASBP Exactly, the Clopidogrel sublingual patent is the real game changer. Turning a blockbuster drug like Plavix into a fast-acting sublingual powder puts Aspire in a different league beyond just supplements. That’s why the current price action is just noise compared to the massive long-term value. We are looking at a potential biotech giant here🚀
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Feb. 3 at 8:16 PM
$ASBP I mean just the one month performance gives you a clue where this is headed
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Feb. 3 at 8:12 PM
$ASBP this is not the stock Stop with this hopepium. Same with IXHl and this. The stock is just garbage 🗑️
0 · Reply
Leo70o
Leo70o Feb. 3 at 8:06 PM
$ASBP the 15,000 shares shown on Fintel are just 'pocket change' and wouldn't drop the stock by a single cent. The market traded over a million shares in the last hour alone, meaning those 15k shares represent less than 1.5% of the volume. What happened wasn’t a short attack; it was actual liquidation from investors spooked by the delay in the compliance news due to the U.S. government shutdown and the SEC being sidelined. We saw nearly half a million shares in net outflow that’s what broke the support and caused the slide, not the tiny bit of short interest you're showing. Shorts are still trapped . they’re just capitalising on the fear of those selling at a discount right now
1 · Reply
todayatatime
todayatatime Feb. 3 at 8:02 PM
$ASBP
0 · Reply
lecorb
lecorb Feb. 3 at 7:58 PM
$ASBP Float: 3.09M Last update : 14 minutes ago Time Since by Fintel Last Change Timestamp (UTC) US:ASBP Short Shares Availability 1 hour ago 2026-02-03 18:36:00.422 6,000 1 hour ago 2026-02-03 18:04:08.61 15,000 1 day ago 2026-02-02 13:02:57.123 0 1 day ago 2026-02-02 12:32:57.123 2,000 1 day ago 2026-02-02 06:18:22.529 3,000 7 days ago 2026-01-27 13:05:10.037 0 7 days ago 2026-01-27 07:47:19.914 10,000 7 days ago 2026-01-27 02:10:16.235 4,000 8 days ago 2026-01-26 15:12:06.829 6,000 8 days ago 2026-01-26 13:04:50.86 7,000
1 · Reply
Juice7162
Juice7162 Feb. 3 at 7:30 PM
$ASBP No worries, the market is down today. Buy and hold.
0 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 7:22 PM
$ASBP buy the dip before the rip!!!
1 · Reply
Megastockmoves2025
Megastockmoves2025 Feb. 3 at 7:21 PM
$ASBP now we move up
0 · Reply
Ricx88
Ricx88 Feb. 3 at 6:55 PM
$ASBP the waiting game dry this volume up get the shorts sweating, borrow rate increasing, tick tock tick tock!
0 · Reply
qfcjhn
qfcjhn Feb. 3 at 6:39 PM
$ASBP This stock is truly Hitchcockian—the suspense is at its peak. Let’s hope that once the 'freeze' is over, it finally takes the direction all of us optimists are waiting for.
0 · Reply